

PERSONAL INFORMATION

Sandro Grelli



📍 University of Rome Tor Vergata, Via Montpellier, 1, 00133 Rome (Italy)
Department of Experimental Medicine
Microbiology and Clinical Microbiology Chair
Via Montpellier, 1, 00133 Rome –Italy

Policlinic Tor Vergata – Virology Unit
Viale Oxford, 81, 00133 Rome - Italy



✉ grelli@med.uniroma2.it

ORCID Researcher unique identifier: 0000-0003-1028-3203
SCOPUS Author ID: 6701796741

Scopus H INDEX 32 cit. 2674

POSITION 2024 to date: Full Professor of Microbiology and Clinical Microbiology, University of Rome Tor Vergata.
2021 Scientific national abilitation (ASN) as Full Professor of Microbiology and Clinic Microbiology (MED 07), Italian Ministry of University and Research (MIUR).

WORK EXPERIENCE

PREVIOUS POSITIONS

2010-2024 Associate professor, at the Department of Experimental Medicine and Biochemical Sciences, University of Rome "Tor Vergata", MED/07, Microbiology e Clinical Microbiology.

1998-2010 University Researcher at the Department of Experimental Medicine and Biochemical Sciences, University of Rome "Tor Vergata", MED/07, Microbiology e Clinical Microbiology.

1994-1998 CNR contract Researcher, at the Institute of Experimental Medicine of the CNR in Rome, for a research program concerning "Programmed cell death, with particular reference to the death of human lymphocytes, connected

with human retrovirus infection ", to be carried out in collaboration with the chair of Microbiology of the University of Rome" Tor Vergata "directed by Prof. Enrico Garaci, from 16.02.1994 to 01.11.1998.

1988-1993 CNR contract Researcher at the Institute of Experimental Medicine of the CNR in Rome, for a research program on "Cellular and Molecular Immunology", to be carried out in collaboration with the chair of Microbiology of the University of Rome "Tor Vergata".

TEACHING ACTIVITY

2018-2024: Director of Specialization course in Microbiology and Virology.

2018-2024 President of the degree course in "Biomedical laboratory diagnostic techniques".

2015 to date: Supervisor of the Biosafety Level 3 Laboratory (BL-3), located within the Laboratory Medicine, Policlinic of Tor Vergata, Rome.

2005 to date: teacher in the Integrated Course of Microbiology, at the University of Tirana (Albania) in the framework of the Collaboration Project between this University and the University of Rome "Tor Vergata".

2002 to date: Member of the Scientific Committee of the PhD course in "Microbiology, immunology, infectious diseases, transplantation and related disease (MIMIT)" and Teacher in Microbiology and Clinical Microbiology for several degree courses.

2002 to date: member of the Board of several Specialization course such as Clinical Pathology and Clinical Biochemistry, Oncology, Ophthalmology, Urology, Dermatology and Venereology and Oral Cavity Surgery, at the University of Rome Tor Vergata.

1997 to date: teaching activities in the degree courses of Medicine and Surgery, Dentistry and Dental Prosthetics, and of Health Professions. He supervised the theoretical-practical and training course and the preparation of the degree and specialization thesis of several students.

1994-1998 collaboration, as an Italian Cooperating Expert, in the scientific-training activities "Strengthening the Medical Research Institute of the University of Alexandria - Egypt ", Funded by the Ministry of Foreign Affairs, for the execution of research projects concerning the " Study of modifications of the T helper type 1 and 2 immunological responses during Schistosoma mansoni infection in mice ", and for the training of young Egyptian researchers.

ASSISTENTIAL POSITION:

Since 2018, he coordinates the Virology Unit and currently participates in the Task Force COVID-19 of Tor Vergata Hospital in Rome. The laboratory has been

identified by the Lazio Region among those authorized to carry out molecular diagnosis on respiratory clinical samples according to specific Real Time PCR protocols for SARS-CoV-2. The Laboratory belongs to the CoroNET network of the Lazio Region, which has the National Institute for Infectious Diseases - IRCCS "Lazzaro Spallanzani" as coordination of all laboratories.

From 1 March 2001 to September 2018, he has the head of the Cellular Immunology and Bacteriological Serology Service at the Tor Vergata Hospital.

EDUCATION AND TRAINING

1985 Master Degree Medicine University of Rome La Sapienza, Italy
1989 Specialization in Oncology at the University of Rome Tor Vergata, Italy
2016 II level University Master Course: "Strategic Acquisition of Technologies for Laboratory Medicine" - IV edition, organized by the LUISS Business.

PERSONAL SKILLS

Mother tongue(s) Italian

Foreign language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	B2	B2	B2	B2	B2

Levels: A1 and A2: Basic user - B1 and B2: Independent user - C1 and C2: Proficient user

Common European Framework of Reference for Languages - Self-assessment grid

Job-related skills

Technical skills in laboratory techniques and research instruments for Cellular Biology, Molecular Biology, Immunology, Bacteriology and Virology. Expert of flow-cytometry. Fluent use of PC, knowing the software for writing, archiving and managing data (Microsoft Office), statistical analysis and graphics (SPSS, Adobe package, Corel Draw), communication and Internet (Explorer, Chrome, Outlook).

ADDITIONAL INFORMATION

MEMBERSHIPS OF SCIENTIFIC SOCIETIES and PARTICIPATION IN COMMITTEES

Since 1997 she is a member of the Italian Society of Microbiology (SIM). Since 2000 is member of the Italian Society of Medical Virology (SIVIM).

RESEARCH ACTIVITIES

He works on different research and multicentre clinical projects regarding infectious diseases, host immune response and novel drugs discovery, focusing on the host-microorganism interaction for the understanding of retroviral infections and the mechanism involved in etiopathogenesis of the associated chronic diseases. His research concerns study on apoptosis and immunological processes in cancer and infections; particularly on apoptotic mechanisms involved in HTLV-1 and HIV infections, evaluation of cytotoxic effects of anticancer and antiretroviral drugs, NF-kB involvement in drug induced apoptosis, identification of biomarkers of prognosis and predictive of the response to treatment for the management of patients.

From 2020 collaborations with industrial partners to develop a project for early intervention in COVID19 patient management based on 1) Flow-cytometry and molecular integrated Multiplex Analysis and 2) the characterization of the expression of endogenous Retroviruses (HERVs) in COVID-19 patients.

In 2018 he is one of the founding members of the Tor Vergata Oncoscience Research (TOR) Center of Excellence, founded at our University on 7/19/2018 with Rector's Decree 1407/2018 (protocol 0024695/2018). The TOR facilitates interaction between local and international science, contributing to the development of the local clinical and academic community in oncology. TOR aims to be a central position in the international network of all European and international cancer research institutes interested in scientific collaboration.

For the Consortium, the scientific activity of Prof. Grelli focuses on the microorganism/host interaction for the understanding of viral infections and the mechanism involved in the etiopathogenesis of associated chronic diseases. Since 1985 he contributed to several research projects concerning studies on multiparametric techniques of cellular analysis for the evaluation of cytotoxic effect of antitumoral and antiretroviral drugs, especially studying the mechanism of apoptosis in lymphoid cell and the involvement of NF-kB in apoptotic response to AZT; immunological modification during antitumoral combination therapy of cytokines and Thymosin alpha 1 in mice; antiviral activity of Thymosin alpha 1; retroviruses (HIV, HTLV-1) and oncogenesis; identification of biological markers for cancer diagnosis and therapy response; evaluation of immunphenotype alterations and cytokine storm in COVID19 patients for biomarkers discovery for early diagnosis and therapeutic choice. Author of about 119 publications among full papers, reviews, meeting proceedings, and more than 200 abstracts from national and international

meetings. Several oral research presentations at international and national scientific meetings, and invited speaker at international meetings.

EDITOR AND REVIEWER FOR INTERNATIONAL JOURNALS:

Member of the Editorial Board of the journal Cell Death and Disease and Biology Direct (2017-2021).

Reviewer in several journals: Frontiers in Immunology, Frontiers in Oncology, Frontiers in Microbiology, BMC Medical and others.

Translation of several books on Clinical and Medical Microbiology, adopted in the Graduate Courses in Medicine and Surgery, Dentistry and Dental Prosthetics, and in those of Health Professions.

SCIENTIFIC PUBLICATIONS: 119 scientific papers published in National and International Journals and over 200 international and national communication abstracts document his experience.

INVESTIGATOR IN RESEARCH PROJECTS

- From July 2024 Principal Investigator (PI) (University of Rome Tor Vergata) Cascade Call COC-1-2023-ISS-01 - Mission 4 "Education and Research" - Component 2 "From Research to Enterprise" -Investment 1. 3 "Creation of partnerships extended to universities, research centers, companies for the funding of basic research projects" for the realization of the project "Severe Infections and Sepsis clinical NETwork for identification of clinical and diagnostic Markers, immunological monitoring and 'Target and tailored' therapies for adults, children and patients admitted to intensive care units /SIS-NET/ID S4-01.P0001" CUP I83C22001810007 - Funded by the European Union - NextGenerationEU.

- 2022: HORIZON-HLTH-2021-DISEASE-04. "HERVCOV- SARS-CoV-2-induced activation of pathogenic endogenous retrovirus envelope HERV-W: towards personalized treatment of COVID-19 patients" (selected for funding, grant agreement in progress), for University of Rome Tor Vergata.

- 2021-RSA funding "AMELIORATE-Innovative markers of early diagnosis and monitoring of respiratory diseases" PI Claudia Matteucci

- 2020 GeNeuro Innovation "Flow-cytometry and molecular integrated Multiplex Analysis for early intervention in COVID19 patient's management" Grant to Claudia Matteucci to support research activity for the understanding of HERVs role in COVID-19 disease.

- 2019-2022: Fellowship Program, Gilead Science: "HIV reservoir and transcriptional activity of endogenous retroviruses (HERVs) and their correlation with the viro-immunological and clinical response in virologically suppressed patients" PI Claudia Matteucci

- 2019-2020: Technical-Scientific Coordinator of the Research Project "Evaluation of the Xpert HIV-1 VIRAL LOAD VL (Chepheid) XC assay" for the

determination of HIV-1 virus viremia".

- 2018-2019: Gilead Fellowship program' Award 2018 Co-participant to "Therapeutic Durability in HIV Infection: development of an ultrasensitive RT-qPCR assay on peripheral blood CD8- cells for assessing the risk of relapse in patients with low-level viremia".
- 2013-2016: Becton Dickinson and INMI Spallanzani. MULTIFIRE: Principal investigator for Tor Vergata Unit of the project: Evaluation of the processes of functional immune reconstitution and immunosenescence in HIV-infected naïve patients undergoing antiretroviral therapy.

PUBLICATIONS (SINCE 2020)

Petrone V, Scutari R, Malagnino V, Piermatteo L, Compagno M, Salpini R, Giudice M, Fanelli M, Teti E, Iannetta M, Minutolo A, Santoro MM, Svicher V, Sinibaldi-Vallebona P, Andreoni M, Balestrieri E, Sarmati L, **Grelli S**, Ceccherini-Silberstein F, Matteucci C. The transactivation of human endogenous retroviruses is associated with HIV-1 reservoir, lymphocyte activation and low CD4 count in virologically suppressed PLWH. *Microbes Infect.* 2025 jul-august;27(5-6):105478. Epub 2025 Jan 31. PMID: 39894201 DOI: 10.1016/j.micinf.2025.105478

1: Costanza G, Felici E, Velluso F, **Grelli S**, Paba P. "Evaluation of ELITE InGenius® integrative system for detection, quantification and monitoring of HIV-1 RNA in Cerebrospinal Fluid.". *J Virol Methods.* 2024 Sep;329:114996. doi:10.1016/j.jviromet.2024.114996. Epub 2024 Jul 27. PMID: 39074515.

2: Macchi B, **Grelli S**, Marino-Merlo F, Mastino A. HTLV-1/2 infection in Italy: a narrative review of epidemiological studies. *AIDS Rev.* 2024 Jun 17;26(2):53-63. doi: 10.24875/AIDSRev.24000007. PMID: 38885479.

3: Ferrari L, Ruggiero A, Stefani C, Benedetti L, Piermatteo L, Andreassi E, Caldara F, Zace D, Pagliari M, Ceccherini-Silberstein F, Jones C, Iannetta M, Geretti AM, et al. EVAN-COV Study Group. Utility of accessible SARS-CoV-2 specific immunoassays in vaccinated adults with a history of advanced HIV infection. *Sci Rep.* 2024 Apr 9;14(1):8337. doi: 10.1038/s41598-024-58597-4. PMID: 38594459; PMCID: PMC11003986.

4: Salpini R, Piermatteo L, Torre G, D'Anna S, Khan S, Duca L, Bertoli A, La Frazia S, Malagnino V, Teti E, Iannetta M, Paba P, Ciotti M, Lenci I, Francioso S, Paquazzi C, Lichtner M, Mastroianni C, Santopaolo F, De Sanctis G, Pellicelli A, Galati G, Moretti A, Casinelli K, Caterini L, Iapadre N, Parruti G, Vecchiet I, Paoloni M, Marignani M, Ceccherini-Silberstein F, Baiocchi L, **Grelli S**, Sarmati L, Svicher V. Prevalence of hepatitis D

virus infection in Central Italy has remained stable across the last 2 decades with dominance of subgenotypes 1 and characterized by elevated viral replication. *Int J Infect Dis.* 2024 Jan;138:1-9. doi: 10.1016/j.ijid.2023.11.005. Epub 2023 Nov 7. PMID: 37944585.

5: Fanelli M, Petrone V, Maracchioni C, Chirico R, Cipriani C, Coppola L, Malagnino V, Teti E, Sorace C, Zordan M, Vitale P, Iannetta M, Balestrieri E, Rasi G, **Grelli S**, Malergue F, Sarmati L, Minutolo A, Matteucci C. Persistence of circulating CD169+monocytes and HLA-DR downregulation underline the immuneresponse impairment in PASC individuals: the potential contribution of different COVID-19 pandemic waves. *Curr Res Microb Sci.* 2023 Dec 12;6:100215. doi: 10.1016/j.crmicr.2023.100215. PMID: 38187999; PMCID: PMC10767315.

6: Piermatteo L, D'Anna S, Bertoli A, Bellocchi M, Carioti L, Fabeni L, Alkhatib M, Frazia S, Lichtner M, Mastroianni C, Sanctis G, Marignani M, Pasquazzi C, Iapadre N, Parruti G, Cappiello G, Vecchiet J, Malagnino V, **Grelli S**, Ceccherini-Silbertein F, Andreoni M, Sarmati L, Svicher V, Salpini R. Unexpected rise in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategies. *Emerg Microbes Infect.* 2023 Dec;12(1):2219347. doi: 10.1080/22221751.2023.2219347. PMID: 37288750; PMCID: PMC10251786.

7: Balestrieri E, Corinaldesi E, Fabi M, Cipriani C, Giudice M, Conti A, Minutolo A, Petrone V, Fanelli M, Miele MT, Andreozzi L, Guida F, Filice E, Meli M, **Grelli S**, Rasi G, Toschi N, Torcetta F, Matteucci C, Lanari M, Sinibaldi Vallebona P. Preliminary Evidence of the Differential Expression of Human Endogenous Retroviruses in Kawasaki Disease and SARS-CoV-2-Associated Multisystem Inflammatory Syndrome in Children. *Int J Mol Sci.* 2023 Oct 11;24(20):15086. doi: 10.3390/ijms242015086. PMID: 37894766; PMCID: PMC10606856.

8: Marino-Merlo F, **Grelli S**, Mastino A, Lai M, Ferrari P, Nicolini A, Pistello M, Macchi B. Human T-Cell Leukemia Virus Type 1 Oncogenesis between Active Expression and Latency: A Possible Source for the Development of Therapeutic Targets. *Int J Mol Sci.* 2023 Sep 30;24(19):14807. doi: 10.3390/ijms241914807. PMID: 37834255; PMCID: PMC10572738.

9: Minutolo A, Gismondi A, Chirico R, Di Marco G, Petrone V, Fanelli M, D'Agostino A, Canini A, **Grelli S**, Albanese L, Centritto M, Zabini F, Matteucci C, Meneguzzo F. Antioxidant Phytocomplexes Extracted from Pomegranate (*Punica granatum* L.) Using Hydrodynamic Cavitation Show Potential Anticancer Activity In Vitro. *Antioxidants*

(Basel). 2023 Aug 4;12(8):1560. doi: 10.3390/antiox12081560.PMID: 37627555

10: Nicolai E, Sarubbi S, Pelagalli M, Basile V, Terrinoni A, Minieri M, Cennamo O, **Grelli S**, Bernardini S, Pieri M. Performance Evaluation of the New Chemiluminescence Immunoassay CL-1200i for HBV, HIV Panels. *Diseases*. 2023 Jun 8;11(2):83. doi: 10.3390/diseases11020083. PMID: 37366871; PMCID: PMC10296845.

11: Petrone V, Fanelli M, Giudice M, Toschi N, Conti A, Maracchioni C, Iannetta M, Resta C, Cipriani C, Miele MT, Amati F, Andreoni M, Sarmati L, Rogliani P, Novelli G, Garaci E, Rasi G, Sinibaldi-Vallebona P, Minutolo A, Matteucci C, Balestrieri E, **Grelli S**. Expression profile of HERVs and inflammatory mediators detected in nasal mucosa as a predictive biomarker of COVID-19 severity. *Front Microbiol*. 2023 May 22;14:1155624. doi: 10.3389/fmicb.2023.1155624. PMID: 37283924; PMCID: PMC10239953.

12: Marino-Merlo F, Klett A, Papaiani E, Drago SFA, Macchi B, Rinco'n MG, Andreola F, Serafino A, **Grelli S**, Mastino A, Borner C. Caspase-8 is required for HSV-1-induced apoptosis and promotes effective viral particle release via autophagy inhibition. *Cell Death Differ*. 2023 Apr;30(4):885-896. doi: 10.1038/s41418-022-01084-y. Epub 2022 Nov 24. PMID: 36418547

13: Minutolo A, Petrone V, Fanelli M, Maracchioni C, Giudice M, Teti E, Coppola L, Sorace C, Iannetta M, Tony Miele M, Bernardini S, Mastino A, Sinibaldi Vallebona P, Balestrieri E, Andreoni M, Sarmati L, **Grelli S**, Garaci E, Matteucci C. Thymosin alpha 1 restores the immune homeostasis in lymphocytes during Post-Acute sequelae of SARS-CoV-2 infection. *Int Immunopharmacol*. 2023 May;118:110055. doi: 10.1016/j.intimp.2023.110055. Epub 2023 Mar 22. PMID:36989892; PMCID: PMC10030336.

14: Favaro M, Zampini P, Pistoia ES, Gaziano R, **Grelli S**, Fontana C. Rapid System to Detect Variants of SARS-CoV-2 in Nasopharyngeal Swabs. *Viruses*. 2023 Jan 26;15(2):353. doi: 10.3390/v15020353. PMID: 36851567; PMCID: PMC9966895.

15: Fanelli M, Petrone V, Buonifacio M, Delibato E, Balestrieri E, **Grelli S**, Minutolo A, Matteucci C. Multidistrict Host-Pathogen Interaction during COVID-19 and the Development Post-Infection Chronic Inflammation. *Pathogens*. 2022 Oct 18;11(10):1198. doi: 10.3390/pathogens11101198. PMID: 36297256; PMCID: PMC9607297.

16: Latini A, Vancheri C, Amati F, Morini E, **Grelli S**, Matteucci C,

Petrone V, Colona VL, Murdocca M, Andreoni M, Malagnino V, Raponi M, Cocciadiferro D, Novelli A, Borgiani P, Novelli G. Expression analysis of miRNA hsa-let7b-5p in naso-oropharyngeal swabs of COVID-19 patients supports its role in regulating ACE2 and DPP4 receptors. *J Cell Mol Med*. 2022 Oct;26(19):4940-4948. doi:10.1111/jcmm.17492. Epub 2022 Sep 8. PMID: 36073344; PMCID: PMC9538662.

17: Marino-Merlo F, Stefanizzi V, Ragno A, Piredda L, **Grelli S**, Macchi B, Mastino A. Quantitative Evaluation of Very Low Levels of HIV-1 Reverse Transcriptase by a Novel Highly Sensitive RT-qPCR Assay. *Life (Basel)*. 2022 Jul 27;12(8):1130. doi: 10.3390/life12081130. PMID: 36013309; PMCID: PMC9410348.

18: Costanza G, Paba P, Ciotti M, Ombres D, Di Carlo S, Marcuccilli F, Bertoli A, Di Traglia L, Mozzani M, Piredda L, Petrone V, Fanelli M, Paganelli C, Cortese B, Balestrieri E, Bernardini S, Andreoni M, Matteucci C, Minutolo A, **Grelli S**. Infection Rate of Respiratory Viruses in the Pandemic SARS-CoV-2 Period Considering Symptomatic Patients: Two Years of Ongoing Observations. *Biomolecules*. 2022 Jul 15;12(7):987. doi: 10.3390/biom12070987. PMID: 35883543; PMCID: PMC9313449.

19: Ferrari L, Compagno M, Campogiani L, Teti E, Mulas T, Checchi D, Alessio G, Caldara F, Coppola L, De Simone G, Ceccarelli L, Spalliera I, Vitale P, **Grelli S**, Andreoni M, Sarmati L, Iannetta M. Increased Mild Vaccine-Related Side Effects and Higher Specific Antibody Titers in Health Care Workers with Previous SARS-CoV-2 Infection after the mRNA BNT162b2 Vaccine. *Vaccines (Basel)*. 2022 Aug;10(8):1238. doi: 10.3390/vaccines10081238. PMID: 36016128; PMCID: PMC9414957.

20: Iacovelli F, Costanza G, Romeo A, Cosio T, Lanna C, Bagnulo A, Di Maio U, Sbardella A, Gaziano R, **Grelli S**, Squillaci E, Miani A, Piscitelli P, Bianchi L, Falconi M, Campione E. Interaction of *Pelargonium sidoides* Compounds with Lactoferrin and SARS-CoV-2: Insights from Molecular Simulations. *Int J Environ Res Public Health*. 2022 Apr 26;19(9):5254. doi: 10.3390/ijerph19095254. PMID: 35564648

22: Coppeta L, Ferrari C, Somma G, Mazza A, D'Ancona U, Marcuccilli F, **Grelli S**, Aurilio MT, Pietroiusti A, Magrini A, Rizza S. Reduced Titers of Circulating Anti-SARS-CoV-2 Antibodies and Risk of COVID-19 Infection in Healthcare Workers during the Nine Months after Immunization with the BNT162b2 mRNA Vaccine. *Vaccines (Basel)*. 2022 Jan 18;10(2):141. doi: 10.3390/vaccines10020141. PMID: 35214600; PMCID: PMC8879462.

23: Alkhatib M, Bellocchi MC, Marchegiani G, **Grelli S**, Micheli V, Stella D, Zerillo B, Carioti L, Svicher V, Rogliani P, Ceccherini-Silberstein F. First Case of a COVID-19 Patient Infected by Delta AY.4 with a Rare Deletion Leading to a N Gene Target Failure by a Specific Real Time PCR Assay: Novel Omicron VOC Might Be Doing Similar Scenario? *Microorganisms*. 2022 Jan 25;10(2):268. doi:10.3390/microorganisms10020268. PMID:35208724; PMCID: PMC8875198.

24: Iannetta M, Landi D, Cola G, Campogiani L, Malagnino V, Teti E, Coppola L, Di Lorenzo A, Fraboni D, Buccisano F, **Grelli S**, Mozzani M, Zingaropoli MA, Ciardi MR, Nisini R, Bernardini S, Andreoni M, Marfia GA, Sarmati L. B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications. *Front Immunol*. 2022 Jan 17;12:796482. doi: 10.3389/fimmu.2021.796482. PMID: 35111162; PMCID: PMC8801814.

25: Minutolo A, Petrone V, Fanelli M, Iannetta M, Giudice M, Ait Belkacem I, Zordan M, Vitale P, Rasi G, Sinibaldi-Vallebona P, Sarmati L, Andreoni M, Malergue F, Balestrieri E, **Grelli S**, Matteucci C. High CD169 Monocyte/Lymphocyte Ratio Reflects Immunophenotype Disruption and Oxygen Need in COVID-19 Patients. *Pathogens*. 2021 Dec 18;10(12):1639. doi: 10.3390/pathogens10121639. PMID: 34959594; PMCID: PMC8715749.

26: Iannetta M, Landi D, Cola G, Malagnino V, Teti E, Fraboni D, Buccisano F, **Grelli S**, Coppola L, Campogiani L, Andreoni M, Marfia GA, Sarmati L. T-cell responses to SARS-CoV-2 in multiple sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-spike antibody titers. *Mult Scler Relat Disord*. 2021 Oct;55:103157. doi: 10.1016/j.msard.2021.103157. Epub 2021 Jul 21. PMID: 34418737; PMCID: PMC8291995.

27: Piermatteo L, Alkhatib M, D'Anna S, Malagnino V, Bertoli A, Andreassi E, Basile E, Iuvara A, De Cristofaro M, Cappiello G, Cerva C, Minichini C, Pisaturo M, Starace M, Coppola N, Fontana C, **Grelli S**, Ceccherini-Silberstein F, Andreoni M, Gill US, Kennedy PTF, Sarmati L, Salpini R, Svicher V. HBeAg Levels Vary across the Different Stages of HBV Infection According to the Extent of Immunological Pressure and Are Associated with Therapeutic Outcome in the Setting of Immunosuppression-Driven HBV Reactivation. *Biomedicines*. 2021 Sep 29;9(10):1352. doi: 10.3390/biomedicines9101352. PMID: 34680469; PMCID: PMC8533134.

28: Aiello F, Ciotti M, Gallo Afflitto G, Rapanotti MC, Caggiano B, Treglia M, **Grelli S**, Bernardini S, Mauriello S, Nucci C, Marsella LT, Mancino R.

Post- Mortem RT-PCR Assay for SARS-CoV-2 RNA in COVID-19 Patients' Corneal Epithelium, Conjunctival and Nasopharyngeal Swabs. J Clin Med. 2021 Sep 20;10(18):4256. doi:10.3390/jcm10184256. PMID: 34575369; PMCID: PMC8464749.

29: Cosio T, Gaziano R, Zuccari G, Costanza G, **Grelli S**, Di Francesco P, Bianchi L, Campione E. Retinoids in Fungal Infections: From Bench to Bedside. Pharmaceuticals (Basel). 2021 Sep 24;14(10):962. doi: 10.3390/ph14100962. PMID: 34681186

30: Rizza S, Coppeta L, **Grelli S**, Ferrazza G, Chiocchi M, Vanni G, Bonomo OC, Bellia A, Andreoni M, Magrini A, Federici M. High body mass index and night shift work are associated with COVID-19 in health care workers. J Endocrinol Invest. 2021 May;44(5):1097-1101. doi: 10.1007/s40618-020-01397-0. Epub 2020 Aug 27. PMID: 32852704

31: Balestrieri E, Minutolo A, Petrone V, Fanelli M, Iannetta M, Malagnino V, Zordan M, Vitale P, Charvet B, Horvat B, Bernardini S, Garaci E, di Francesco P, Sinibaldi Vallebona P, Sarmati L, **Grelli S**, Andreoni M, Perron H, Matteucci C. Evidence of the pathogenic HERV-W envelope expression in T lymphocytes in association with the respiratory outcome of COVID-19 patients. EBioMedicine. 2021 Apr;66:103341. doi: 10.1016/j.ebiom.2021.103341. Epub 2021 Apr 15. PMID: 33867312; PMCID: PMC8082064.

32: Minutolo A, Potesta` M, Roglia V, Cirilli M, Iacovelli F, Cerva C, Fokam J, Desideri A, Andreoni M, **Grelli S**, Colizzi V, Muleo R, Montesano C. Plant microRNAs from *Moringa oleifera* Regulate Immune Response and HIV Infection. Front Pharmacol. 2021 Feb 11;11:620038. doi: 10.3389/fphar.2020.620038. eCollection 2020. PMID: 33643043

33: Pieri M, Nuccetelli M, Nicolai E, Sarubbi S, **Grelli S**, Bernardini S. Clinical validation of a second generation anti-SARS-CoV-2 IgG and IgM automated chemiluminescent immunoassay. J Med Virol. 2021 Apr;93(4):2523-2528. doi: 10.1002/jmv.26809. Epub 2021 Jan 26. PMID: 33463719; PMCID: PMC8013349.

34: Novelli G, Liu J, Biancolella M, Alonzi T, Novelli A, Patten JJ, Cocciadiferro D, Agolini E, Colona VL, Rizzacasa B, Giannini R, Bigio B, Goletti D, Capobianchi MR, **Grelli S**, Mann J, McKee TD, Cheng K, Amanat F, Krammer F, Guarracino A, Pepe G, Tomino C, Tandjaoui-Lambiotte Y, Uzunhan Y, Tubiana S, Ghosn J; COVID Human Genetic Effort; French COVID Cohort Study Group; CoV- Contact Cohort; Notarangelo LD, Su HC, Abel L, Cobat A, Elhanan G, Grzymski JJ, Latini A, Sidhu SS, Jain S, Davey RA, Casanova JL, Wei W, Pandolfi PP. Inhibition of HECT E3 ligases as potential therapy for COVID-19. Cell

Death Dis. 2021 Mar 24;12(4):310. doi: 10.1038/s41419-021-03513-1. PMID: 33762578; PMCID: PMC7987752.

35: Matteucci C, Minutolo A, Balestrieri E, Petrone V, Fanelli M, Malagnino V, Ianetta M, Giovinazzo A, Barreca F, Di Cesare S, De Marco P, Miele MT, Toschi N, Mastino A, Sinibaldi Vallebona P, Bernardini S, Rogliani P, Sarmati L, Andreoni M, **Grelli S**, Garaci E. Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells From Coronavirus Disease 2019 Patients. *Open Forum Infect Dis*. 2020 Dec 5;8(1):ofaa588. doi: 10.1093/ofid/ofaa588. PMID: 33506065; PMCID: PMC7798699.

36: Salpini R, Battisti A, Piermatteo L, Carioti L, Anastasiou OE, Gill US, Di Carlo D, Colagrossi L, Duca L, Bertoli A, La Rosa KY, Fabeni L, Iuvara A, Malagnino V, Cerva C, Lichtner M, Mastroianni CM, De Sanctis GM, Paoloni M, Marignani M, Pasquazzi C, Iapadre N, Parruti G, Vecchiet J, Sarmati L, Andreoni M, Angelico M, **Grelli S**, T Kennedy P, Verheyen J, Aquaro S, Silberstein FC, Perno CF, Svicher V. Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection. *Emerg Microbes Infect*. 2020 Dec;9(1):928-939. doi: 10.1080/22221751.2020.1757998. PMID: 32312174

37: Macchi B, Frezza C, Marino-Merlo F, Minutolo A, Stefanizzi V, Balestrieri E, Cerva C, Sarmati L, Andreoni M, **Grelli S**, Mastino A. Appraisal of a Simple and Effective RT-qPCR Assay for Evaluating the Reverse Transcriptase Activity in Blood Samples from HIV-1 Patients. *Pathogens*. 2020 Dec 13;9(12):1047. doi: 10.3390/pathogens9121047. PMID: 33322208; PMCID: PMC7763350.

38: Amati F, Vancheri C, Latini A, Colona VL, **Grelli S**, D'Apice MR, Balestrieri E, Passarelli C, Minutolo A, Loddo S, Di Lorenzo A, Rogliani P, Andreoni M, Novelli G. Expression profiles of the SARS-CoV-2 host invasion genes in nasopharyngeal and oropharyngeal swabs of COVID-19 patients. *Heliyon*. 2020 Oct;6(10):e05143. doi: 10.1016/j.heliyon.2020.e05143. Epub 2020 Oct 1. PMID: 33024851; PMCID: PMC7528978.

39: Pellicciaro M, Granai AV, Marchese G, Materazzo M, Cotesta M, Santori F, Giacobbi E, Servadei F, **Grelli S**, Perretta T, Meucci R, Pistolese CA, Vanni G. Breast cancer patients with hormone neoadjuvant bridging therapy due to asymptomatic Corona virus infection. Case report, clinical and histopathologic findings. *Int J Surg Case Rep*. 2020;76:377-380. doi: 10.1016/j.ijscr.2020.10.020. Epub 2020 Oct 8. PMID: 33052300

40: Novelli A, Biancolella M, Borgia P, Cocciadiferro D, Colona VL,

D'Apice MR, Rogliani P, Zaffina S, Leonardis F, Campana A, Raponi M, Andreoni M, **Grelli S**, Novelli G. Analysis of ACE2 genetic variants in 131 Italian SARS- CoV-2-positive patients. Hum Genomics. 2020 Sep 11;14(1):29. doi: 10.1186/s40246-020-00279-z. PMID: 32917283; PMCID: PMC7483483.

41 Potesta` M, Roglia V, Fanelli M, Pietrobono E, Gismondi A, Vumbaca S, Nguedia Tsangueu RG, Canini A, Colizzi V, **Grelli S**, Minutolo A, Montesano C. Effect of microvesicles from *Moringa oleifera* containing miRNA on proliferation and apoptosis in tumor cell lines. Cell Death Discov. 2020 Jun 4;6:43. doi: 10.1038/s41420-020-0271-6. eCollection 2020.PMID: 32550010

42: Nuccetelli M, Pieri M, **Grelli S**, Ciotti M, Miano R, Andreoni M, Bernardini S. SARS-CoV-2 infection serology: a useful tool to overcome lockdown? Cell Death Discov. 2020 May 26;6:38. doi: 10.1038/s41420-020-0275-2. PMID: 32501411; PMCID:PMC7249039.

Rome, 01/08/2026

